Made With Uberflip Content Marketing

Latest Content

Insight provides timely coverage of news that influences the business strategies of the life science industry. It is also the source for up-to-date information on leading industry partnering events.

  • Biotech Startups: Land and conduct a successful investor meeting

    Biotech Startups: Land and conduct a successful investor meeting

    Biotech startup companies face many challenges, but one of the most common is landing and conducting meetings with potential investors. The following are pieces of advice from investors on what...

    Read
  • How can startup companies get noticed by potential investors and partners?1:22

    How can startup companies get noticed by potential investors and partners?

    Access the industry's premier life science partnering event, BioPharm America™ in Boston September 26–27, 2017, to connect with strategic partners and get your innovation funded. No other event combin

    Watch Video
  • Where are they now? EpiAxis Therapeutics channels successes into scientific and business development

    Where are they now? EpiAxis Therapeutics channels successes into scientific and business development

    EpiAxis Therapeutics is channeling its success at BioPharm America™’s Startup Day into success at the business and scientific levels. Since finishing first for best “investment pitch quality and...

    Read
  • BioPharm America September 26-27

    Learn More
  • Where are they now? Cocoon Biotech planning tox studies

    Where are they now? Cocoon Biotech planning tox studies

    Recognition from a high profile organization like the BioPharm America™ conference has been tremendous for Cocoon,” Ailis Tweed-Kent, MD, founder and CEO of Cocoon Biotech says. Winning the...

    Read
  • Where are they now? For Virvio, it’s all about visibility

    Where are they now? For Virvio, it’s all about visibility

    When Virvio participated in BioPharm America™’s Startup Day pitch contest in 2016, the company had been operational less than one year. It had three employees and was operating under grants from...

    Read
  • Download the Digital Medicine Whitepaper

    Click here
  • Bruce Levine is a man you can thank for your future cell therapy

    Bruce Levine is a man you can thank for your future cell therapy

    To call Bruce Levine, PhD, an innovator in the cell and gene therapy space is a gross understatement. He is known for his groundbreaking work in the development and use of synthetic immune cells...

    Read
  • ChinaBio® Partnering Forum 2017: Rapid change: Good times for pharma?56:06

    ChinaBio® Partnering Forum 2017: Rapid change: Good times for pharma?

    Everything in China seems to be on the fast track. This is especially true in the pharma industry, where new announcements affecting regulations, pricing, and reimbursement are occurring on nearly a d

    Watch Video
  • ChinaBio® Partnering Forum 2017: Funding drug development in China through VCs and partnerships1:01:21

    ChinaBio® Partnering Forum 2017: Funding drug development in China through VCs and partnerships

    Western and China companies are leveraging the significant funding and support available in China to develop their assets more cost effectively and efficiently. 2016 set another record in VC funds rai

    Watch Video
  • ChinaBio® Partnering Forum 2017: HitGen aids China drug discovery with DNA library7:36

    ChinaBio® Partnering Forum 2017: HitGen aids China drug discovery with DNA library

    Wei Chen, head of R&D for Chengdu-based HitGen describes to Scrip’s Brian Yang how the Chinese startup partners with multinationals to speed up new drug development in China, and planned IND filing fo

    Watch Video
  • ChinaBio® Partnering Forum 2017: Sirnaomics prioritizes China in parallel with US RNAi development15:06

    ChinaBio® Partnering Forum 2017: Sirnaomics prioritizes China in parallel with US RNAi development

    Alan Y. Lu, Executive VP of Sirnaomics, discusses with Scrip’s Brian Yang how the US-China hybrid looks to develop RNAi therapies simultaneously in the two countries. RNAi is relatively new in China,

    Watch Video
  • Pursuing Excellence: Charting Industry's Top Performances

    Download Now
  • ChinaBio® Partnering Forum 2017: China's EpimAb hunts for novel biologics with funding, partnership8:16

    ChinaBio® Partnering Forum 2017: China's EpimAb hunts for novel biologics with funding, partnership

    Dr. Wu Chengbin, CEO and founder of Shanghai-based EpimAb Biotherapeutics discusses with Scrip’s Brian Yang how the startup's preparatory platform will develop next-generation bispecific antibodies.

    Watch Video
  • ChinaBio® Partnering Forum 2017: China's HEC Pharm enters America with novel IPF treatment7:00

    ChinaBio® Partnering Forum 2017: China's HEC Pharm enters America with novel IPF treatment

    Tommy Lin, head of Business Development and Global Licensing for HEC Pharm outlines for Scrip’s Brian Yang how the Chinese domestic drug company looks to develop its liver drug in the US. On May 2, t

    Watch Video
  • ChinaBio® Partnering Forum 2017: ConSynance tests waters in China with differentiated NASH asset8:10

    ChinaBio® Partnering Forum 2017: ConSynance tests waters in China with differentiated NASH asset

    Dr. Shuang Liu, president and co-founder of upstate New York-based ConSynance Therapeutics discusses with Scrip’s Brian Yang the startup's plan to develop and commercialize its multiple assets in vari

    Watch Video
  • Download "Finding Finance" Industry Report

    Click Here
  • ChinaBio® Partnering Forum 2017: Roche looks to real-world data and IT to drive partnering in China11:33

    ChinaBio® Partnering Forum 2017: Roche looks to real-world data and IT to drive partnering in China

    Mark Noguchi, Global Head, Alliance and Asset Management at Roche discusses with Scrip’s Brian Yang the Swiss biotech's plan to tap into emerging IT for partnering opportunities in China. Roche has be

    Watch Video
  • Tissue regeneration: A vital area within regenerative medicine

    Tissue regeneration: A vital area within regenerative medicine

    Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence and Nancy Dvorin, Executive Editor, In Vivo Cell and gene therapies often get the lion’s...

    Read
  • The Advocate of Rare Disease Advocates: Remembering Henri Termeer

    The Advocate of Rare Disease Advocates: Remembering Henri Termeer

    We were saddened to come to work Monday morning to discover that innovator, industry giant and Genzyme founder Henri Termeer had died. We had the pleasure of working with Termeer over the years as...

    Read
  • Where to start: How to gain a foothold in the China biopharmaceutical market

    Where to start: How to gain a foothold in the China biopharmaceutical market

    The China pharmaceutical market has come of age. With record breaking investments in innovative companies, support from the CFDA, and new product approvals pending, China has entered a new age as...

    Read
  • Health tech innovators pitch business ideas to expert panel at BIO-Europe Spring®

    Health tech innovators pitch business ideas to expert panel at BIO-Europe Spring®

    The buzz steadily grew as the Health Tech Competition got underway on the last day of BIO-Europe Spring® March 22 in Barcelona. As delegates filed into the competition room, the energy was...

    Read
  • The Digital Medicine Crystal Ball

    The Digital Medicine Crystal Ball

    How will digital technologies impact disease management and healthcare over the next decade? Find out in the just-released whitepaper, “The Digital Medicine Crystal Ball: Unlocking the Future of...

    Read
  • Rare Disease Foundation CEO cites collaboration, data sharing as keys to progress

    Rare Disease Foundation CEO cites collaboration, data sharing as keys to progress

    An interview with Monica Weldon, President of Bridge the Gap – SYNGAP Education and Research Foundation Houston-based Monica Weldon is a mother, wife, former teacher and a rare disease advocate...

    Read
  • Report findings provide insight into technological innovations and trends in drug development

    Report findings provide insight into technological innovations and trends in drug development

    Knect365 Life Sciences has released a report offering unique insights into the awareness, perceptions and implementation of technological innovations in the drug development industry. Based on a...

    Read
  • BIO-Europe Spring® 2017: Commercializing cell and gene therapies59:40

    BIO-Europe Spring® 2017: Commercializing cell and gene therapies

    New business models for clinical development and manufacturing require strategic partnerships among researchers, manufacturers and payers to fully realize the commercial opportunities.

    Watch Video
  • BIO-Europe Spring® 2017: Partnerships are key for rare disease drug discovery and development8:00

    BIO-Europe Spring® 2017: Partnerships are key for rare disease drug discovery and development

    What kinds of partnerships are key to getting rare disease research out of the lab and to patients as therapies and cures? Wendy White, Board Chairman of Global Genes, discusses her work on behalf of

    Watch Video
  • BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets8:34

    BIO-Europe Spring® 2017: Sinergium provides gateway to Latin American vaccine and biologics markets

    With the Latin American vaccines market forecast to more than quadruple in size from just over USD 150 million to 2015 to just under USD 700 million in 2020, opportunities abound for both homegrown bu

    Watch Video
  • BIO-Europe Spring® 2017: TxCell plans first-in-man trial of regulatory T cells9:41

    BIO-Europe Spring® 2017: TxCell plans first-in-man trial of regulatory T cells

    Having completed a Phase I/IIa study of Ovasave, a drug candidate from its first generation non-modified antigen-specific regulatory T cells (Tregs), TxCell expects to start a first-in-man study of a

    Watch Video
  • BIO-Europe Spring® 2017: Korean pharma spawns US cancer biotech startup9:25

    BIO-Europe Spring® 2017: Korean pharma spawns US cancer biotech startup

    HanAll, a Korean generics and drug reformulation business, has established a US biotech based on research it funded to utilize cellular metabolism to develop novel and immuno-oncology therapies. Dr. B

    Watch Video
  • BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs9:24

    BIO-Europe Spring® 2017: Imanova trims Phase I and IIa trial timelines and costs

    Dr. Kevin Cox, CEO of Imanova, the UK-based translational biomedical imaging company, explains to Scrip’s Mike Ward how his company can help biotechs and pharma firms cut the cost of Phase I and IIa t

    Watch Video
  • VIDEO: Innovation in an uncertain world

    VIDEO: Innovation in an uncertain world

    How are cutting-edge biotech companies trying to compete in a global marketplace dealing with drug-price anger, science skepticism, and policies to close borders and protect jobs? Read more »

    Read
  • BIO-Europe Spring® 2017: Avir BD execs on innovative meds for Canadians4:15

    BIO-Europe Spring® 2017: Avir BD execs on innovative meds for Canadians

    Located in Quebec, Canada, Avir Pharma, a specialty pharma company, is part of the Laboratoire Riva group. Its primary focus is to acquire, license or co-develop innovative medicines with an end aim o

    Watch Video
  • BIO-Europe Spring® 2017: vitalityDNA plans to keep healthy individuals healthy9:27

    BIO-Europe Spring® 2017: vitalityDNA plans to keep healthy individuals healthy

    Precision medicines, an increased interest in the microbiome and a growing focus on wellness are some of the latest trends gripping the healthcare industry. London-based startup vitalityDNA is combini

    Watch Video
  • BIO-Europe Spring® 2017: Mitochondrial medicine focus drives NeuroVive orphan ambitions9:16

    BIO-Europe Spring® 2017: Mitochondrial medicine focus drives NeuroVive orphan ambitions

    Underpinned by a profound understanding of genetic mitochondrial disorders, Swedish biotech NeuroVive Pharmaceutical AB is pursuing a two-pronged orphan and speciality pharma approach. CEO Erik Kinnma

    Watch Video
  • BIO-Europe Spring® 2017: Shanghai Henilus Biotech has blockbuster biologics in biosimilar crosshairs8:28

    BIO-Europe Spring® 2017: Shanghai Henilus Biotech has blockbuster biologics in biosimilar crosshairs

    With a number of monoclonal blockbusters—notably Roche’s Rituxan and Herceptin—approaching patent expiry in key markets, it is not surprising that a queue is forming to create biosimilar competitors.

    Watch Video
  • BIO-Europe Spring® 2017: Producing monoclonals for at least a tenth of the cost8:04

    BIO-Europe Spring® 2017: Producing monoclonals for at least a tenth of the cost

    Dutch antibody technology company BiosanaPharma is offering to make monoclonal antibodies at between 5% and 10% the usual cost of manufacture. Dr. Nettie Buitelaar, the company’s chief business office

    Watch Video
  • BIO-Europe Spring® 2017: Venneos develops next generation label-free cell analysis6:15

    BIO-Europe Spring® 2017: Venneos develops next generation label-free cell analysis

    Cell-based assays play a crucial role in drug discovery, toxicity testing and have the potential to contribute new insights into cellular behavior. However, many have limitations such as requiring lab

    Watch Video
  • Q1 2017 – Advanced Therapies Make a Strong Showing Early in the Year

    Q1 2017 – Advanced Therapies Make a Strong Showing Early in the Year

    Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence and Nancy Dvorin, Executive Editor, In Vivo Advanced therapy companies started 2017 with a...

    Read
  • Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III

    Using Partnerships, Hua Medicine Brings Novel Diabetes Drug to Phase III

    Li Chen, PhD, co-founded Hua Medicine (Shanghai) six years ago with Ge Li, PhD, founder of WuXi AppTec. The company soon in-licensed global rights to a GKA treatment for type 2 diabetes from...

    Read
  • BIO-Europe Spring® 2017: Stirring the entrepreneurial pot in Europe1:01:16

    BIO-Europe Spring® 2017: Stirring the entrepreneurial pot in Europe

    Europe is home to many of the biggest pharma companies and the best academic biomedical researchers. But the US is the dominant place with thriving hubs of biotech entrepreneurs, people taking big ris

    Watch Video
  • BIO-Europe Spring® 2017:  Infant Bacterial Therapeutics harnesses microbiome to treat preterm babies12:54

    BIO-Europe Spring® 2017: Infant Bacterial Therapeutics harnesses microbiome to treat preterm babies

    By harvesting Lactobacillus reuteri from lactating mothers, Infant Bacterial Therapeutics has developed an approach to treat necrotizing enterocolitis, a major killer of premature babies. Company CEO

    Watch Video
  • BIO-Europe Spring® 2017: Digimed and diagnostics: Market access and new collaborations59:50

    BIO-Europe Spring® 2017: Digimed and diagnostics: Market access and new collaborations

    The effect of digital medicine on diagnostics is having and will continue to have a revolutionary effect on the interactions between patients and their healthcare providers and between the healthcare

    Watch Video
  • BIO-Europe Spring® 2017: Incorporating flexibility into your R&D strategy52:52

    BIO-Europe Spring® 2017: Incorporating flexibility into your R&D strategy

    Strategic decisions made early in clinical development often have an impact on the downstream commercial potential of an asset. This is true for both large pharma and emerging biotech companies. What

    Watch Video
  • BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones8:01

    BIO-Europe Spring® 2017: Newron CEO on Xadago and upcoming pipeline milestones

    Newron CEO Stefan Weber discusses the company's Parkinson's therapy, Xadago (safinamide), on the eve of its US market approval during the recent BIO-Europe Spring partnering conference. Newron, a clin

    Watch Video
  • BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities10:02

    BIO-Europe Spring® 2017: Seventure Partners predicts bright future for microbiome opportunities

    Seventure Partners’ Eric de la Fortelle explains to Informa Pharma Intelligence’s Mike Ward how the venture capitalist’s EUR 160 million fund will prosper from the increased understanding of human and

    Watch Video
  • BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech5:47

    BIO-Europe Spring® 2017: Sofinnova chairman discusses entrepreneurial culture change in biotech

    Antoine Papiernik is the chairman of Paris-based Sofinnova Partners, a venture capital firm that invests in startups and spinout biotech companies primarily in Europe. He spoke with Luke Timmerman, th

    Watch Video
  • BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy8:12

    BIO-Europe Spring® 2017: Prexton CEO on future for novel Parkinson's therapy

    As Prexton Therapeutics prepares to move its lead compound foliglurax into Phase II trials as a symptomatic treatment for Parkinson’s disease, CEO Francois Conquet talks to Scrip about the company's t

    Watch Video
  • BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice8:16

    BIO-Europe Spring® 2017: Ergomed's evolution and risk-sharing business model in practice

    Over the last decade Ergomed has evolved from a contract research organization into a clinical-stage drug development company. Chief business officer Andrew Mackie tells Scrip more about this transfor

    Watch Video
  • BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline9:39

    BIO-Europe Spring® 2017: Genentech's BD head spotlights neuroscience pipeline

    Thomas Zioncheck, global head of business development for neuroscience, ophthalmology, and research tools and technology at Genentech, talks to Scrip about the company's early-stage partnering strateg

    Watch Video
  • BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs7:00

    BIO-Europe Spring® 2017: Biomunex CEO on earlier deals for cancer drugs

    During the recent BIO-Europe Spring partnering conference in Barcelona, Biomunex CEO Pierre-Emmanuel Gerard chats with Scrip about the company's strategy for partnering with pharmas in the cancer drug

    Watch Video
  • BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment11:27

    BIO-Europe Spring® 2017: Atriva repurposes cancer drug candidates to create universal flu treatment

    Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors original

    Watch Video
  • BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans6:13

    BIO-Europe Spring® 2017: Biomunex CSO defines lead compounds, early R&D plans

    During BIO-Europe Spring 2017 in Barcelona, Eugene Zhukovsky, chief scientific officer at Biomunex speaks to Scrip about the company's bispecific antibody pipeline and how its candidates are different

    Watch Video
  • BIO-Europe Spring® 2017: Chronic constipation device impresses judges in startup competition5:55

    BIO-Europe Spring® 2017: Chronic constipation device impresses judges in startup competition

    usMIMA is a team of scientists and engineers that has developed a solution for chronic constipation. The group won second place in BIO-Europe Spring's 2017 Healthtech Startup competition. MowoOT is fo

    Watch Video
  • BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations5:09

    BIO-Europe Spring® 2017: Noxxon CEO discusses partners and cancer combinations

    Noxxon CEO Aram Mangasarian talks to Scrip about development plans for the company's lead compound NOX-A12, which is being tested as a combination therapy for a number of cancer indications. NOX-A12 i

    Watch Video
  • BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies8:22

    BIO-Europe Spring® 2017: Celyad VP talks IP issues, development timelines for CAR-T therapies

    Georges Rawadi, VP of business development and intellectual property at Celyad, discusses the company's CAR-T pipeline, recently resolved IP issues and the firm's strategy for future clinical developm

    Watch Video
  • Can pharma afford to cure patients instead of treating them?

    Can pharma afford to cure patients instead of treating them?

    Who wants a one-shot therapy that delivers a durable response in patients? What is the price for a cure that payers are willing to pay? Why is pharma turning its attention away from this...

    Read
  • BIO Report: Funding cools down after five-year run while early deals stay hot

    BIO Report: Funding cools down after five-year run while early deals stay hot

    Across five metrics for biotech financings tracked by BIO, the sector saw steep drops in 2016 due to uncertainty introduced by political upheavals and regulatory reforms. Yet in each category the...

    Read
  • Startup Slam: Compelling pitch for Peptomyc takes the prize

    Startup Slam: Compelling pitch for Peptomyc takes the prize

    The third round of this fast-paced parade of presentations pitted 14 promising entrepreneurs in a winner-take-all competition. The reward includes tailored mentoring with the scientists and...

    Read
  • Mounting uncertainty threatens research and innovation in medicines

    Mounting uncertainty threatens research and innovation in medicines

    Regulatory reforms, political upheavals and proposed cuts to research funding create an uncertain and increasingly risky landscape for companies developing new medicines. The life sciences...

    Read
  • Biotechs successfully navigate alternative paths to financing

    Biotechs successfully navigate alternative paths to financing

    Project awards, strategic venture funds and now crowd-funding offer alternatives to traditional venture funds for emerging biotech companies. Pfizer's new strategic fund or the well-established...

    Read
  • POLs: Patient opinion leaders emerge as key to success in orphan drug designation

    POLs: Patient opinion leaders emerge as key to success in orphan drug designation

    Orphan drugs are wicked hot. Wall Street loves them. And patients are a powerful force that can make or break a decision to grant that coveted designation for your drug. But don't count on having...

    Read
  • Facing increased complexity, oncology trial sites tighten up procedures

    Facing increased complexity, oncology trial sites tighten up procedures

    Financing a Phase I trial in oncology is tough, but completing a successful trial for a novel drug candidate is even tougher. An army of specialists is required, and then comes the challenge of...

    Read
  • Digital medicine takes small steps toward Big Data

    Digital medicine takes small steps toward Big Data

    Across a fragmented European landscape multiple programs advance the digitization of data as building blocks for advanced analytics. Read more »

    Read
  • BIO-Europe Spring® 2017: Key considerations in microbiome partnering1:01:03

    BIO-Europe Spring® 2017: Key considerations in microbiome partnering

    The human microbiome is garnering research interest across the globe and industry is responding to the growing possibilities of therapeutic developments in a variety of ways, a key aspect of which is

    Watch Video
  • BIO-Europe Spring 2017 kicks off this week in Barcelona

    BIO-Europe Spring 2017 kicks off this week in Barcelona

    Read
  • Report gives substance to fast-paced scientific discoveries in microbiome

    Report gives substance to fast-paced scientific discoveries in microbiome

    Guest post by Eric de La Fortelle, Venture Partner at Seventure Partners Microbes are everywhere, and apart from the occasional pathogen, they are a positive force for health maintenance. Indeed...

    Read
  • 2016 – A Year in Review for Advanced Therapies

    2016 – A Year in Review for Advanced Therapies

    Guest post by Patricia Reilly, M.S., Head of Intelligence Alliances and Unification, Pharma Intelligence | Informa The past year saw intensifying dialogue on how to assess the value of and...

    Read
  • Stirring the Pot for Entrepreneurship in European Tech Transfer

    Stirring the Pot for Entrepreneurship in European Tech Transfer

    Guest post by Luke Timmerman, founder and editor of the Timmerman Report, and a regular contributor to Forbes and STAT News. The science in many parts of Europe is first-rate. No one disputes...

    Read
  • World RARE Disease Day shines a light on rare disease community

    World RARE Disease Day shines a light on rare disease community

    Tomorrow is the 10th annual World RARE Disease Day. Various activities are taking place all over the United States as well as countless locations around the world. World RARE Disease Day is an...

    Read
  • Barcelona biotech companies shine light on regional entrepreneurship

    Barcelona biotech companies shine light on regional entrepreneurship

    Investors are always on the lookout for innovative biotech startups, and the Catalonia, Spain biopharma cluster has plenty to offer in the way of innovation from among its member companies....

    Read
  • Increase the value of your asset: Think with the end in mind

    Increase the value of your asset: Think with the end in mind

    Developing a drug is a very long journey, therefore it is critical to define the destination upfront. The Target Product Profile is like a postcard of your desired destination. It informs the data...

    Read
  • What’s the deal with Immuno-oncology partnering?

    What’s the deal with Immuno-oncology partnering?

    Insight wanted to get the lay of the I/O landscape, so who better to speak with than Jeff Bockman, Vice President of Defined Health. Not only was Jeff kind enough to share his insights with us,...

    Read
  • Why the connected patient is the killer app in the digital age of medicine

    Why the connected patient is the killer app in the digital age of medicine

    Guest article by Deb Kilpatrick, PhD, CEO at Evidation Health and Rich Milani, MD, FACC, FAHA, Chief Clinical Transformation Officer at Ochsner Health System If you search on the phrase “killer...

    Read
  • Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona’s GP Pharm considers partnering key to international expansion

    Barcelona is an attractive location for business and trade, and has experienced a revival in the biopharma sector in recent years with the outsourcing of innovation from pharma companies to...

    Read
  • Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Welcome to Barcelona—one of the most vibrant life sciences hubs in Europe

    Guest article by BIOCAT, the Bioregion of Catalonia After the great success of previous editions (2010 and 2013), the Bioregion of Catalonia is again hosting BIO-Europe Spring® 2017 (March 20–22),...

    Read
  • Realities of Rare Disease and the Role of Patient Investors

    Realities of Rare Disease and the Role of Patient Investors

    Guest post by Nicole Boice, Founder & CEO, Global Genes – Allies in Rare Disease Rare Disease represents the largest disease community on the planet!  With over 7,000 identified diseases,...

    Read
  • Finding Finance: Pharma, Biotech & Medtech Capital Raising 2016

    Finding Finance: Pharma, Biotech & Medtech Capital Raising 2016

    Read Flipbook
  • Digital medicine: Invest in innovation

    Digital medicine: Invest in innovation

    It’s too soon to say, definitively, whether digital medicine will be disruptive or adjunctive for drug developers or even the entire healthcare system. Even the business models are in flux. What...

    Read
  • Pharma Industry Report: Top 10 Drugs

    Pharma Industry Report: Top 10 Drugs

    Read Flipbook
  • How Do Healthcare Investors and Payers Separate the Tools From the Toys?

    How Do Healthcare Investors and Payers Separate the Tools From the Toys?

      Guest post by Nicole Fisher, Founder & CEO at HHR Strategies, Inc., Forbes Contributor The healthcare sector does not behave like other industries when it comes to money. First, attracting...

    Read
  • Partnering in the Pharma World: BIO-Europe® and industry trends 2012-2015

    Partnering in the Pharma World: BIO-Europe® and industry trends 2012-2015

    Read Flipbook
  • UK Establishment upbeat about Brexit’s effect on British life science industry

    UK Establishment upbeat about Brexit’s effect on British life science industry

    Brexit may no longer be at the top of popular news, but it continues to be a key concern for biopharma companies in post-Brexit 2017. The sentiment of key players from the UK life sciences from a...

    Read
  • Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception9:11

    Biotech Showcase™ 2017: Janssen focuses cardiometabolic R&D on prevention, cure and interception

    With readouts in important trials of key drugs Invokana and Xarelto on the horizon, Dr. James F. List, Global Therapeutic Area Head of Cardiovascular and Metabolism, has plenty of reasons for insomnia

    Watch Video
  • Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta10:13

    Biotech Showcase™ 2017: Flexion gears up to commercialize Zilretta

    Following submission of new drug application of Zilretta (FX006) for knee osteoarthritis in mid-December 2016, Flexion Therapeutics CEO Mike Clayman is hoping for priority review of the filing, in add

    Watch Video
  • Finding the value of real-world evidence

    Finding the value of real-world evidence

    Real-world evidence isn’t about what happens in the clinic, but is just as important to your success. It’s the application of analytics to real-world data collected outside the realm of...

    Read
  • Taming the Wild West of digital medicine

    Taming the Wild West of digital medicine

    The new paradigm of healthcare is widely becoming known as “The Digital Health Revolution,” referring to medical technology advancements so great that when combined with wearables, medication...

    Read
  • Investors’ appetite for the life sciences continued in 2016

    Investors’ appetite for the life sciences continued in 2016

    Guest post by Doro Shin, Thought Leadership Manager at Informa Pharma Intelligence While 2015 was a record year for investments within the life sciences industry, investors became wary toward the...

    Read
  • Rare diseases, rare commitment

    Rare diseases, rare commitment

    Patients, their families and patient foundations are invaluable in helping drug developers understand the day-to-day realities of approx. 7,000 rare diseases (of which only 400 have therapies)....

    Read
  • Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America8:28

    Biotech Showcase™ 2017: J&J poised to establish no-strings-attached JLABS outside America

    As Johnson & Johnson announced the establishment of its eighth JLABS facility, in collaboration with New York State and the New York Genome Center, Melinda Richter, head of Johnson & Johnson Innovatio

    Watch Video
  • Thirteen young people bucking the odds, finding paths to break into biotech

    Thirteen young people bucking the odds, finding paths to break into biotech

    Guest post by Luke Timmerman, founder and editor of the Timmerman Report, and a regular contributor to Forbes and STAT News. Walking around San Francisco’s Union Square during biotech conference...

    Read
  • Digital Health Security: The Most Important Tradeoff Between Ease and Privacy

    Digital Health Security: The Most Important Tradeoff Between Ease and Privacy

    Guest post by Nicole Fisher, Founder & CEO at HHR Strategies, Inc., Forbes Contributor Wayne Gretzky always said it’s better to look where the puck is going, not where it is now. The introduction...

    Read
  • The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The state of cell and gene therapy: Reimbursement and manufacturing dominate

    The number of cell therapies in clinical trials has grown 21 percent since 2015, with more than 759 trials underway globally. With that growth it is time for the industry to get serious about...

    Read
  • Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates6:06

    Biotech Showcase™ 2017: Reinventing Arena to focus on Phase II clinical candidates

    In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq, which it has partnered with Eisai; spinning out t

    Watch Video
  • Industry pundit Joe Hage on medtech innovation in 2017

    Industry pundit Joe Hage on medtech innovation in 2017

    Joe Hage, a medical device marketing consultant, is well known in medtech circles. In particular, he runs one of the largest and possibly most successful LinkedIn groups, the “Medical Devices...

    Read
  • Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Unmet needs, uncommon commitment: The shift toward investment in rare diseases

    Join biotech leaders, emerging innovators, investors and patient advocacy group reps for a candid, interactive and enlightening discussion about rare disease drug discovery and development. Read...

    Read
  • The renaissance of gene therapy

    The renaissance of gene therapy

    Gene therapy and gene editing are at the beginning of a renaissance, according to speakers at Biotech Showcase™ 2017. While sizeable challenges exist, they are being overcome, leaving the field...

    Read
  • Digital Health: Smart Devices Were Just The Beginning

    Digital Health: Smart Devices Were Just The Beginning

    The connectivity that will be created by the convergence of computers and health will truly alter the way knowledge, technology and insights into the future revolutionize health care.

    Read
  • Who gets funded? Imaginative companies!

    Who gets funded? Imaginative companies!

    The biotech industry needs a new approach that approximates the type of disruption that Uber brought to transportation and Amazon and eBay brought to retail sales. Instead of embracing those lean...

    Read
  • Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

    Pulse, prognosis and the press: Journalists discuss key biotech trends for 2017

    As the intensity of Biotech Week in San Francisco winds down, join our exclusive panel of all-star reporters for their unique take on the news, trends and issues that will reverberate in 2017 and...

    Read
  • Biotech Showcase™ 2017: Payer environment will impact biopharma prospects in 2017

    An increased focus on the need to access and develop truly transformational medicines was a key theme in the hallway chatter at this year’s Biotech Showcase/JP Morgan Healthcare meetings. Michael Hay,

    Watch Video
  • Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Breaking down the “four walls” of patient care: What is the state of the digital medicine industry?

    Amid tirelessly pursuing possible partnerships and investment opportunities to bring revolutionary medical products to market at Biotech Showcase™ 2017 in San Francisco, global executives were...

    Read
  • Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients7:53

    Biotech Showcase™ 2017: Double-barreled approach doubles survival times in recurrent glioma patients

    Brain cancer remains one of the deadliest diseases, and little to no effective treatments exist. Marty Duvall, newly appointed CEO of San Diego-based gene therapy technology company Tocagen, tells Mik

    Watch Video
  • Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML12:05

    Biotech Showcase™ 2017: MEI Pharma rides wave of interest in AML

    Following a Phase II release of data for its oral histone deacetylase (HDAC) inhibitor pracinostat in the tough-to-treat acute myeloid leukemia (AML), MEI Pharma CEO Dan Gold says he is optimistic hea

    Watch Video
  • Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery8:05

    Biotech Showcase™ 2017: Second Genome CEO predicts paradigm shift with microbiome discovery

    Microbiome discovery and development will trigger the next major paradigm shift in medicine, more profound than the discovery of recombinant DNA, Second Genome CEO Glenn Nedwin predicted in an intervi

    Watch Video
  • Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery8:05

    Biotech Showcase™ 2017: PhaseRx makes more noise than silence with mRNA delivery

    Having ditched RNA silencing in 2012, PhaseRx president and CEO Dr. Robert Overell explains to Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, how delivering

    Watch Video
  • It’s all happening at Biotech Showcase™ Week

    It’s all happening at Biotech Showcase™ Week

    Guest post by Constantine Theodoropulos, President, GO Therapeutics Thankfully there is a holiday between now and Biotech Showcase™ Week in San Francisco (Jan 9–11), because we are going to need...

    Read
  • Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity9:36

    Biotech Showcase™ 2017: CBMG aims for large-scale CAR-T capacity

    Cellular Biomedicine Group (CBMG) CEO Bizuo (Tony) Liu differentiates plans for chimeric antigen receptor-T cell development in part by large-scale production in the company's home country, China. In

    Watch Video
  • Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

    Lifetime trends in biopharmaceutical innovation: Recent evidence and implications

    Guest blog post by Murray Aitken, Executive Director of the QuintilesIMS Institute Adequate returns on life sciences investments underpin the sustainability of the innovation lifecycle.   And...

    Read
  • loading
    Loading More...